A Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia

March 10, 2017
HS 2016-3250
Alzheimer’s, Memory disorders, Memory loss, Dementia
Aimee L. Pierce, MD
UCI campus (UCI MIND Gottschalk Medical Plaza, ICTS in Hewitt Hall Neuroscience Imaging Center in Irvine Hall) in Irvine
To evaluate whether an investigational drug known as JNJ-54861911 can reduce amyloid beta fragments, a hallmark component of the amyloid plaques that accumulate in Alzheimer's disease.
Male and female participants ages 60 to 85 with evidence of elevated brain amyloid (performed at screening by Positron Emission Tomography or lumbar puncture)
Screening phase (up to 60 days) and treatment phase (32 visits over 54 months)

You may or may not experience any benefit from being in this study. If you are in the group that receives the study drug, JNJ-54861911, and it proves to be effective in reducing amyloid beta fragments better than the placebo, you may benefit from participating in the study, but this cannot be guaranteed.

The information collected from this study may increase knowledge regarding the treatment of Alzheimer's disease and help people in the future.

  • $50 for each completed MRI scan; there are 6 MRI scans ($300 max)
  • $100 for each completed amyloid PET scan; there are 3 optional amyloid PET scans ($300 max)
  • $100 for each completed lumbar puncture; there are 3 optional lumbar punctures ($300 max)
  • $100 for each yearly clinic visit (at months 12, 24, 36 and 48) ($400 max)

The grand total compensation for this study is a maximum of $1,300 in cash.

Participants will not be reimbursed for travel-related expenses.


Huong Nguyen, Clinical Trials Research Inquiry Coordinator